{"id":"ethiodized-oil-based-emulsion","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatic toxicity"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ethiodized oil is an iodinated poppy seed oil that provides radiographic contrast for imaging procedures. When formulated as an emulsion, it can be used as a carrier for chemotherapy or as an immunotherapeutic agent. The iodine content provides radiopacity for visualization, while the oil-based formulation may enhance cellular uptake and trigger immune-mediated antitumor effects through activation of innate immunity.","oneSentence":"Ethiodized oil-based emulsion acts as a radiopaque contrast agent and immunomodulatory agent that enhances imaging and may stimulate immune responses against cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:11:43.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (transarterial chemoembolization or immunotherapy)"}]},"trialDetails":[{"nctId":"NCT07293468","phase":"PHASE2, PHASE3","title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":106},{"nctId":"NCT07100405","phase":"","title":"TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-08-15","conditions":"Hepatocellular Carcinoma","enrollment":50},{"nctId":"NCT03268499","phase":"NA","title":"Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2016-09-09","conditions":"Hepatocellular Carcinoma","enrollment":80},{"nctId":"NCT06497140","phase":"PHASE3","title":"Effect of Genicular Arteries Embolization in Symptomatic Knee Osteoarthritis LipioJoint-2","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09-30","conditions":"Knee Osteoarthritis","enrollment":130},{"nctId":"NCT05631613","phase":"","title":"Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhongda Hospital","startDate":"2022-12-28","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT04967482","phase":"NA","title":"DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2021-07-09","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":216},{"nctId":"NCT05472896","phase":"PHASE3","title":"TACE With Dicycloplatin(TP21) in Unresectable HCC","status":"UNKNOWN","sponsor":"Gao-jun Teng","startDate":"2022-06-09","conditions":"Hepatocellular Carcinoma","enrollment":332},{"nctId":"NCT05053386","phase":"NA","title":"Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-10","conditions":"Hepatocellular Carcinoma","enrollment":186},{"nctId":"NCT03116984","phase":"PHASE3","title":"A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2017-01-01","conditions":"Hepatocellular Carcinoma","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ethiodized Oil-based emulsion","genericName":"Ethiodized Oil-based emulsion","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ethiodized oil-based emulsion acts as a radiopaque contrast agent and immunomodulatory agent that enhances imaging and may stimulate immune responses against cancer cells. Used for Hepatocellular carcinoma (transarterial chemoembolization or immunotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}